Se ha denunciado esta presentación.
Utilizamos tu perfil de LinkedIn y tus datos de actividad para personalizar los anuncios y mostrarte publicidad más relevante. Puedes cambiar tus preferencias de publicidad en cualquier momento.

Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

The Only Industry Event Solely Dedicated to Optimising the Applications CRISPR Precision Genome Editing in Europe.
Overcome key specificity, efficiency & delivery challenges to pioneer drug discovery, biomedical research and therapeutic applications of precision genome engineering. With customisation of CRISPR design paramount, join leading biopharma and academic figureheads as they reveal advanced methodology, strategies and clinical timelines to fulfil the revolutionary promise of precision genome editing.

Audiolibros relacionados

Gratis con una prueba de 30 días de Scribd

Ver todo
  • Sé el primero en comentar

Updated Agenda- CRISPR Congress in Berlin, 24-26 October 2016

  1. 1. Harnessing Precision Genome Editing Applications for Advanced Biomedical Research & Therapeutic Development Tel: +44 (0)20 3141 8700 | Email: info@hansonwade.com CRISPR Precision Gene Editing Researched & Developed By:www.crispr-europe.com 24th-26th October 2016 | Berlin, Germany Lead Partner Additional Partners Book now and save up to 4400 Bill Lundberg CRISPR Therapeutics John Feder Bristol-Myers Squibb Daniel Anderson MIT John van der Oost Wageningen UR Danilo Maddalo Novartis Institutes for BioMedical Research Lennart Randau Max-Planck-Institute
  2. 2. 1 1 3 3 2 2 4 4 5 5 Advance your understanding of CRISPR and Cas9 mechanisms to optimise downstream applications of precision gene-editing technology Explore how Max-Planck are taking learnings from CRISPR/Cas structures and mechanisms in bacteria to identify target specificity Develop optimised workflows to effectively integrate CRISPR technology into basic and biomedical research Learn how Pfizer are integrating CRISPR technology for optimised target validation through CRISPR libraries Integrate CRISPR technology in disease modelling and genome-wide screening to advance target identification and validation Discover how Takeda Cambridge are developing customized designed IPS cells for in vitro disease modelling Top 5 Key Takeaways Top 5 Ideas to Implement Understand the regulatory environment for utilising CRISPR technology in crop breeding and take those learnings into your industry Learn from Karolinska Institutet & Novartis on how to harness CRISPR- based genome-wide screening for optimised target identification Harness precision gene engineering to develop cell-based therapies in oncology Discover how Cellectis are clinically utilising TALENs to develop CAR-T therapies Benefits of Attending Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing The Only Industry Congress Solely Dedicated to Optimising the Applications of CRISPR Precision Genome Editing in Europe Develop your CRISPR workflows to power novel applications in target identification, disease modelling and therapeutic development The CRISPR & Precision Genome Editing Congress Europe 2016 will continue to enhance and improve the very latest applications of CRISPR technology to pioneer basic research, biomedical research and therapeutic applications of precise genome engineering. With customisation and optimisation of CRISPR design paramount, join leading biopharma and academic figureheads as they reveal advanced methodology, strategies and clinical timelines to fulfil the revolutionary promise of precision genome editing. With beneficial applications of CRISPR increasing and alternative systems rapidly being developed, safeguard against future technical bottlenecks faced by early adopters and new users alike by learning how to optimise CRISPR workflows to enhance the integration of precision gene editing within your research. Discover how the industry is advancing the robustness of current applications of CRISPR including: disease modelling, target identification and validation, genome-wide screening and development of CRISPR therapeutics. Furthermore, as it establishes itself as the leading editing tool, discover future applications on the horizon. In this truly innovative field, become part of the CRISPR Europe Congress in 2016 and join those dedicated to pioneering CRISPR/Cas9 to enhance applications in basic research to R&D productivity and revolutionise therapeutic development.
  3. 3. Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing Expert Speaker Faculty Donald Apanovitch Director, Functional Genomics & Biolomics Pfizer Daniel Anderson Sam Goldblith Associate Professor MIT Bill Lundberg Chief Scientific Officer CRISPR Therapeutics Ross Kettleborough European Field Applications Specialist Twist Bioscience Danilo Maddalo Lab Head, Oncology Pharmacology Novartis Institutes for BioMedical Research Lennart Randau Research Group Leader, Terrestrial Microbiology Max-Planck-Institute John Feder Associate Director, Genome Biology Bristol-Myers Squibb John van der Oost Professor, WU Agrotechnology & Food Sciences Wageningen UR Jonathan Chesnut Senior Director, Synthetic Biology R&D Thermo Fisher Scientific Evren Alici Assistant Professor & Research Group Leader Karolinska Institutet Roderick Beijersbergen Group Leader, Division of Molecular Carcinogenesis & NKI Robotics & Screening Center The Netherlands Cancer Institute Steve Sheardown Transgenic Group Head Takeda Cambridge Laurent Poirot Head of Early Discovery Cellectis Emma Shanks Head of Screening The Beatson Institute Jennifer Berman Staff Scientist, Applications, Digital Biology Center Bio-Rad Laboratories Kosuke Yusa Group Leader Wellcome Trust Sanger Institute Alexander Espinosa Assistant Professor Karolinska Institutet Niels Geijsen Founder & Scientific Advisor NTrans Petra Jorasch Vice Secretary General German Plant Breeders’ Association Beat Späth Director Agricultural Biotechnology EuropaBio Maria Celeste M. Ramirez Director of Product Marketing Twist Bioscience Leigh Brody Director Genomic Services Desktop Genetics Daniela Hüber Gene Modulation Specialist, Dharmacon GE Healthcare Speakers all gave excellent presentations - perfect balance of both academic and industry viewpoints on leveraging CRISPR technology. I enjoyed the format and structured networking sessions were well thought out. I also appreciated the opportunity to connect with new experts in this emerging field Past Attendee, Warp Drive Bio
  4. 4. Pre-Conference Workshops, Monday 24th October 2016 Workshop A Workshop B I really enjoyed all the talks and the variety in them, from pure academic to industrial application. I thought the meeting was excellent and well-worth it Past Attendee, Broad Institute I was able to get something out of each presentation. It was a total success in my opinion Past Attendee, GlaxoSmithKline Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing One key application of CRISPR precision gene editing is in the discovery and functional understanding of genomics through high-throughput screening. In this interactive workshop, you will capitalise lessons learned in order to: • Optimise the implementation of CRISPR gene editing for target identification and validation • Discuss technical strategies to improve CRISPR applications both in vitro and in vivo utilisation • Harness protocols and strategies for large scale genome screens to develop CRISPR libraries CRISPR/Cas9-mediated genome editing has become a rapidly adopted application in developing in vitro and in vivo preclinical models to better understand the complexity of human disease. In this interactive workshop, you will discover solutions and answers to help you: • Discover the impact of genome editing tools in preclinical investigation in industry • Overcome the current limitations of using CRISPR for disease modelling • Learn about and discuss case studies to standardise protocols to utilise CRISPR for in vitro and in vivo models • Discover what information can we get from in vivo models Enhancing CRISPR Technology for Target Identification and Developing Genome-Wide CRISPR Libraries within Oncology Date: Monday 24th October 2016 Time: 9.00-12.00 Developing More Physiologically-Relevant Disease Models With CRISPR for Improved Preclinical Predictability Date: Monday 24th October 2016 Time: 13.00-16.00 Danilo Maddalo Lab Head, Oncology Pharmacology Novartis Institutes for BioMedical Research Donald Apanovitch Director, Functional Genomics & Biolomics Pfizer About Your Workshop Leader: At Memorial Sloan Kettering Cancer Center, Dr Maddalo established a model of chromosomal rearrangements using the CRISPR/Cas9 technology. Dr Maddalo, now at Novartis Institutes for Biomedical Research in Basel, focuses on mouse modelling of disease for drug discovery and target identification. Very enjoyable and informative meeting. The workshops at the beginning were something new to me and I found them a very useful means of idea sharing and networking Past Attendee, Boehringer Ingelheim About Your Workshop Leader: Donald manages the Functional Genomics group in the Biolomics Department at Pfizer Research. The group is responsible for supporting the validation and/ or identification of new therapeutic targets across multiple therapeutic research areas using multiple high content imaging platforms and RNAi technologies.
  5. 5. Conference Day One, Tuesday 25th October 2016 8.00 Registration & Breakfast 9.00 Chairman’s Opening Remarks Scalpel Precision: Empowering CRISPR to be Even More Precise 9.10 A CRISPR Screen Identifies Genetic Vulnerabilities in Acute Myeloid Leukaemia • Development and improvement of the CRISPR screening methodology for optimised CRISPR workflows • Applications of CRISPR gene editing for screening in oncology research • Developing screening and libraries to identify genetic vulnerabilities in cancer cells Ross Kettleborough, European Field Applications Specialist, TWIST Bioscience Kosuke Yusa, Group Leader, Wellcome Trust Sanger Institute 9.40 Understanding the Mechanistic Actions of Cpf1 to Optimise Efficiency of CRISPR Precision Genome Editing • Addressing Cpf1 mechanisms and how it is currently being applied • Comparing and contrasting the mechanisms of Cpf1 to Cas9 • What is the current efficiency readout for Cpf1 compared to Cas9? John van der Oost, Professor, WU Agrotechnology & Food Sciences, Wageningen UR 10.10 Modulating the Architecture of Minimal Type I CRISPR-Cas Interference Complexes • Reviewing the landscape of highly divergent CRISPR-Cas systems in prokaryotes • Highlighting important structural and functional differences, which can impact target specificity • Discussing the structural and targeting mechanisms, and the assembly of Cas protein interference complexes termed Cascade Lennart Randau, Research Group Leader, Terrestrial Microbiology, Max-Planck-Institute 10.40 Speed Networking & Morning Refreshments Improving Customised Design of CRISPR Workflows & Effective Data Analysis 11.40 Ultra-Sensitive Quantification of Genome Editing Events by Droplet Digital PCR • Development and optimisation of genome editing methods for a sensitive, rapid-readout tool for edit validation and off-target detection • Droplet Digital PCR (ddPCR) enables sensitive (<0.1%), precise absolute quantification of NHEJ and HDR alleles in a rapid, high-throughput format Jennifer Berman, Staff Scientist, Applications, Digital Biology Center, Bio-Rad Laboratories 12.10 Transitioning From siRNA Screens to CRISPR Screens: Experiences From The Beatson Institute • Utilising high throughput functional genomics approaches with high content phenotypic image analysis for target identification and validation across multiple cancer types using both immortal and primary cell cultures derived from patient tumours • Transitioning from siRNA-based screens using both pooled and deconvolved approaches • Exploring the value of adding CRISPR to our workflow as a screening tool by conducting i) genome-wide pooled sgRNA screens and ii) arrayed sgRNA phenotypic screens • Comparative sgRNA and siRNA array evaluations using scalable cytotoxic, cytostatic and cell migration platforms • Evaluations using our PhenoTox panel, containing targets generating apoptotic, autophagic, senescent, oxidative stress and ER stress phenotypes Emma Shanks, Head of Screening, The Beatson Institute 12.40 CRISPR-Based Genome Editing Tools: New Applications & Improved Workflows • Streamline and high throughput CRISPR tool production • Discussing improvements in gene knock-out and editing efficiency • Evaluating new and efficient platforms for CRISPR-based functional genomics screening Jonathan Chesnut, Senior Director, Synthetic Biology R&D, Thermo Fisher Scientific Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing
  6. 6. 13.10 Networking Lunch Advancing Disease Modelling & Large Scale Genome-Wide Screening 14.10 Genome Editing Meets Mouse Modelling for Better Preclinical Tools • Highlighting the limitations of traditional mouse models • Harnessing CRISPR for the precise development of physiologically relevant preclinical in vivo models • Examples how genome editing as a tool has been utilised to generate better preclinical models Danilo Maddalo, Lab Head, Oncology Pharmacology, Novartis Institutes for BioMedical Research 14.40 The Possibilities, Challenges & Success of CRISPR-Based Screening for Target Identification • Development and optimisation of screening models using CRISPR technology • Selection of the best screening strategy • Selection and follow-up of screening hits Roderick Beijersbergen, Group Leader, Division of Molecular Carcinogenesis & NKI Robotics & Screening Center, The Netherlands Cancer Institute 15.10 Harnessing Fluorescent Properties of Small-Molecules for CRISPR/Cas9 Screens • Developing CRISPR screening protocols for target identification in oncology • To harness the fluorescent properties of many anti-cancer drugs to identify unknown drug targets and to understand mechanisms of drug resistance Alexander Espinosa, Assistant Professor, Karolinska Institutet 15.40 Afternoon Refreshments & Poster Competition Hosted by Twist Bioscience With an agenda packed with case studies and data-driven presentations, the CRISPR Europe poster session will allow you deeper access into the most innovative research. Meet the scientists conducting exciting research and pick their brains to gain insights into the emerging CRISPR gene editing applications. Apply their learnings straight into your own work, cultivate research collaborations and leave inspired by new ideas. 16.25 Interactive CRISPR Roundtable Discussions In this one hour session, you will have the opportunity to choose from four different topics and catch up on the latest advancements and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following: 17.25 Close of Day 1 17.30 Drinks Reception Hosted by Twist Bioscience Ethics and impact CRISPR/Cas-9 for human germline editing 1. 2. 3. 4. Correcting mutations in human genetic diseases Preparing for clinical trials involving therapies based on CRISPR-Cas9 Applications within genome editing and transcriptome modulation Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing
  7. 7. Conference Day Two, Wednesday 26th October 2016 7.30 Breakfast & Networking 8.30 Chairman’s Opening Remarks Regulatory Landscape of CRISPR Across Industries 8.40 Panel Discussion: Navigating the Regulatory Environment for CRISPR as Novel Breeding Technique With the advent of cheaper and faster gene sequencing technology and advanced genomics, precision gene editing provides an opportunity to add back useful characteristics by reintroducing some of the lost diversity in a more targeted manner to accelerate the breeding process. As the agricultural industry will be leading the way in receiving regulatory approval to produce and market CRISPR edited crops and plants, what lessons learnt can other industries take from the regulatory process? The panel will discuss and answer the following questions: • What opportunities do technologies like CRISPRs afford? • What can be learned from the long history of safe use of random mutagenesis in the development of useful new crop characteristics? • How will the method of deploying new technologies like CRISPRs affect the regulatory profile in plants and microbes? • How might the outcomes achieved by new technologies like CRISPRs affect the regulatory profile in plants and microbes? • What are the industry responsibilities? Session Chair: Petra Jorasch, Vice Secretary General, German Plant Breeders’ Association Beat Späth, Director Agricultural Biotechnology, EuropaBio 9.25 Keynote Session: Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing • High throughput, combinatorial approaches have revolutionized small molecule drug discovery • Here we describe our work on high throughput methods for developing and characterizing RNA delivery and gene editing systems • Libraries of degradable polymers and lipid-like materials have been synthesized, formulated and screened for their ability to delivery RNA, both in vitro and in vivo • A number of delivery formulations have been developed with in vivo efficacy, and show potential therapeutic application for the treatment of genetic disease, viral infection, and cancer Daniel Anderson, Sam Goldblith Associate Professor, MIT 9.55 Morning Refreshments Clinical Utility: Therapeutic Applications of CRISPR Gene Editing 10.25 Development and Optimisation of CRISPR Gene Editing for Drug Discovery Applications • Genome engineering is advancing at an incredible pace however applications across the types of translational and predicative cell models now preferred for drug target discovery remains a challenge • What areas of the drug discovery process will genome engineering have the biggest and most immediate impact? • How does the pharmaceutical industry evaluate and implement a technology that is evolving so rapidly especially as it relates to the creation of genetic disease models in iPSCs? John Feder, Associate Director, Genome Biology, Bristol-Myers Squibb Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing
  8. 8. 10.55 TALEN-Based Genome Editing for Adoptive T-Cell Therapies • Harnessing talen genome editing technology for clinical applications • Utilising talen-mediated genome editing in allogeneic T cells for adoptive immunotherapy • CAR T cell therapies will require genome editing to reach their full potential Laurent Poirot, Head of Early Discovery, Cellectis 11.25 iTOP: A Novel Non-Viral Delivery System for Gene-Editing Based Therapeutics • Development of the iTOP technology, a proprietary platform technology for the intracellular delivery of bioactive molecules • Highly efficient in vivo delivery of recombinant proteins • In vivo application in CRISPR-Cas9 mediated gene repair Niels Geijsen, Founder & Scientific Advisor, NTrans 11.55 Bringing CRISPR Therapeutics into the Clinic • How are CRISPR gene editing approaches distinct from the older gene therapy or nuclease methods? • What important considerations need to be addressed as we bring CRISPR therapeutics into clinical stage testing in patients? • Which therapeutic areas are currently being investigated using precision gene engineering? • What technical hurdles need resolving for successful clinical translation of CRISPR technology? Bill Lundberg, Chief Scientific Officer, CRISPR Therapeutics 12.25 Networking Lunch Pioneering CRISPR in Drug Discovery & Target Identification 13.25 CRISPR-Cas9 Screening with Arrayed Synthetic crRNA Libraries • Discuss key factors for success with arrayed crRNA screening • Discover benefits of synthetic dual CRISPR guide RNA • Evaluate screening results using high content analysis with a cell cycle reporter line Daniela Hüber, Gene Modulation Specialist, Dharmacon, GE Healthcare 13.55 Keynote Session: Strategies & Applications Using CRISPR and RNAi Technologies for Identification of Novel Oncology Druggable Targets • Genome editing approaches to accelerate drug discovery, target identification, validation & whole genome screening • Genome editing technology could be employed as a screening tool for identifying or validating potential cancer genes for therapeutic development Donald Apanovitch, Director, Functional Genomics & Biolomics, Pfizer 14.40 Harnessing CRISPR Genome Editing for the Development of Cancer Immunotherapies • Highlighting protocol optimisation steps for CRISPR workflows • Addressing how CRISPR gene editing is being used in NK cells for oncology patient screening Evren Alici, Assistant Professor & Research Group Leader, Karolinska Institutet 15.10 Enhancing the Takeda Cambridge Drug Discovery Toolkit with CRISPR/Cas9 • How we use CRISPR to improve efficiency and remove bottlenecks in the rodent transgenic production pipeline • Generating human-relevant models in vitro; our experiences using CRISPR/Cas9 to catalyse somatic/iPS cell knockout and knockin, and the preferred strategies that we have adopted • Looking ahead, some thoughts on how we might improve reproducibility and confidence in in vitro genome engineered systems Steve Sheardown, Transgenic Group Head, Takeda Cambridge 15.40 Afternoon Refreshments 17.10 Chair’s Closing Remarks 17.15 Close of CRISPR & Precision Genome Editing Congress Europe 2016 Reimagine CRISPR Workflows with Precision Guides From Design to Synthesis 16.10 Interactive Workshop Hosted by Twist Bioscience With customisation and optimisation of CRISPR design paramount, learn how to optimise CRISPR workflows to enhance the integration of precision gene editing and down stream applications of CRISPR technology within your research. In this interactive workshop, you will discover solutions and answers to help you: • Overview on library design techniques for optimising CRISPR workflows • Understand the impact of high quality DNA synthesis on enabling accurate editing • Using specific examples of how these libraries are used in translational research to highlight the potential applications towards development of novel molecular therapeutics Workshop Leaders: Leigh Brody, Director Genomic Services, Desktop Genetics Maria Celeste M. Ramirez, Director of Product Marketing, Twist Bioscience Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing
  9. 9. Partners Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing Twist Bioscience Our expertise is synthetic DNA. We have developed a manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools. Our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid and high-quality synthetic gene production. The Twist Bioscience platform has the potential to accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. www.twistbioscience.com Lead Partner Thermo Fisher Scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life Sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. www.thermoscientific.com Programme Partner Bio-Rad Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics. www.bio-rad.com Programme Partner Dharmacon – part of GE Healthcare Dharmacon has revolutionized the field of RNA synthesis with the introduction of 2’-ACE synthesis chemistry since 1995. As leaders in custom RNA synthesis, Dharmacon was an early participant in the newly discovered field of RNA interference, and contributed several key scientific findings. Dharmacon RNAi products were some of the first commercially available. In addition, Dharmacon offers a unique set of CRISPR-Cas9 gene editing tools. The Dharmacon CRISPR-Cas9 platform greatly simplifies the workflow of permanently knocking out genes. www.dharmacon.gelifesciences.com Programme Partner Cibus Cibus is the leader in non-transgenic breeding & precision gene editing in agriculture. Our mission is to improve plants and other organisms with a new class of non-transgenic breeding technologies. These work without integrating foreign genetic material thus the resulting organisms are non-transgenic. Since our improvements are non-transgenic, they will be globally acceptable. The company has developed & patented advanced breeding technologies that enable precise, stable, predictable changes to be made in plants and other organisms without integrating foreign genetic material. www.cibus.com Programme Partner
  10. 10. Become a Partner: Partnership Opportunities: Contact Diane McKenna Commercial Director, Genomics Tel: +44 (0)203 141 8700 Email: sponsor@hansonwade.com As a result of the meeting we currently are involved in active negotiations with three companies we met there and are in question-answering stage with others. Almost too much interest for us to handle! MD, Director, Washington University School of Medicine This meeting is designed to describe the profound impact CRISPR is having on basic research and therapeutic development. It explored the research tools, bioinformatics and expertise needed to make the most of this breakthrough technology Horizon Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing Merck Merck Millipore and Sigma-Aldrich have come together as the life science business of Merck KGaA, Darmstadt, Germany. With a portfolio spanning more than 300,000 products, including a diverse range of CRISPR reagents, whole genome screening libraries (including Sanger arrayed and GeCKO pooled libraries), validation services and technical expertise, our company is committed to solving the toughest problems in life science. For more information, visit: www.merckmillipore.com www.sigma-aldrich.com Exhibitor Ntrans NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences. The iTOP intracellular delivery technology is based on a combination of small molecule compounds which forces the uptake of large gulps of extracellular fluid (containing the bioactive molecules) by the cell. Once inside, the vesicles release their content into the cytoplasm, where the bioactive molecules can exert their therapeutic action. Our goal is to further support distribution and commercialization of the iTOP technology for the research community and to develop a therapeutic platform for iTOP based delivery of bioactive molecules. The NTrans mission is to translate the unique iTOP technology into revolutionary new therapies for the treatment of genetic diseases and cancer. www.ntranstechnologies.com The CRISPR & Precision Genome Editing Congress is a dedicated to enhance the very latest applications of CRISPR. This is where VPs, Directors and C-Level Executives from Pharma, Biotech and Academia are coming to search for the right partners. This Congress enables the field to establish long term partnerships to secure future success. Network with new clients and cement existing relationships via speed networking, personal introductions and multiple industry-wide touch points. There is no one size fits all approach to partnership at CRISPR Congress Europe 2016. When you work with us we will build a partnership that helps you achieve those aims. Several opportunities exist to educate the industry on your product or service including speaking positions, exhibiting and hosting receptions. Demonstrate thought leadership, showcase expertise and educate the CRISPR community about your capabilities. Programme Partner
  11. 11. * All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation. Register Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the four- teenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH Terms & Conditions Code:6507VAT will be charged at 19% VAT will be charged at 19% Pricing & Venue Venue Pricing I will certainly come back to the CRISPR Congress. I have attended several conferences about genome editing, but CRISPR Congress stands out among them. Past Attendee Standard Pricing Register & Pay before 30th September 2016 Standard Price* Gold: Conference + 2 Workshops 23297 + VAT (Save 4400) 23497 + VAT (Save 4200) Silver: Conference + 1 Workshop 22798 + VAT (Save 4300) 22998 + VAT (Save 4100) Bronze: Conference Only 22299 + VAT (Save 4200) 22499 + VAT Workshop (Each) 2599 + VAT Academic Pricing Register & Pay before 30th September 2016 Standard Price* Gold: Conference + 2 Workshops 21917 + VAT (Save 4300) 22017 + VAT (Save 4200) Silver: Conference + 1 Workshop 21658 + VAT (Save 4200) 21758 + VAT (Save 4100) Bronze: Conference Only 21399 + VAT (Save 4100) 21499 + VAT Workshop (Each) 2359 + VAT Tel: +44 (0)20 3141 8700 Email: info@hansonwade.com www.crispr-europe.com CRISPR & Precision Gene Editing Congress Europe Berlin, Germany | 24th -26th October 2016 CRISPR Precision Gene Editing Hotel Palace Berlin Budapester, Str. 45 10787, Berlin, Germany Accommodation: Overnight accommodation is not included in the registration fee www.crispr-europe.com/register Tel: +44 (0)20 3141 8700 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU • 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Team discounts cannot be applied to academic pricing. Team Discounts*

×